(3.231.25.104)
Users online: 2268    [ij] [ij] [ij] 
Email id
 

Research Journal of Pharmacy and Technology
Year : 2018, Volume : 11, Issue : 3
First page : ( 1041) Last page : ( 1047)
Print ISSN : 0974-3618. Online ISSN : 0974-360X.
Article DOI : 10.5958/0974-360X.2018.00195.6

Detection of Mutation in codon 12 of KRAS gene in Iraqi patients with colorectal Adenocarcinoma

Zayed Karrar Saleem*

Department of Laboratory Investigations, Faculty of Science, University of Kufa, Iraq

*Corresponding Author E-mail: karrars.alshebly@uokufa, edu.iq

Online published on 7 July, 2018.

Abstract

KRAS gene mutations in codon 12 are detected remarkably in high occurrence in Iraqi patients with colorectal adenocarcinoma. This study aims to investigate the mutations in codon 12 of this gene in colorectal tumor specimens. Fresh biopsies samples were collected from one hundred and twenty colorectal cancer (CRC)patients and one hundred (ulcerative colitis) as non-malignant negative control for revealing mutations in KRAS (codon 12) using restriction fragment length polymorphism-polymerase chain reaction (RFLP-PCR), mutations were compared between patients and negative control, clinicopathologic features (age, gender, tumor size, grade, stage and tumor site) were compared between mutated and wild-type KRAS in CRC patients. Heterozygous mutations in KRAS codon 12 were significant only in individuals with CRC 52 of 120 (43.33%) when compared with non-malignant control group (ulcerative colitis) 0 (0%) (P<0.001), Odd ratio was 1.765; 95% CI was (1.7652.202), other CRC patients were present in wild-type homozygotes 68(56.66%). High mean age, well-moderate grade, stage II and recto-sigmoid tumor was significant in association with heterozygous KRAS mutation in codon 12 than homozygous wild-type of CRC patients (P<0.05). Mutation in codon 12 KRAS is regarded as aprognostic marker used for early diagnosis of CRC, also it determines which patient responds to anti-EGFR targeted antibodies treatment.

Top

Keywords

KRAS mutation, codon 12, exon 2, colorectal adenocarcinoma, and RFLP.

Top

  
║ Site map ║ Privacy Policy ║ Copyright ║ Terms & Conditions ║ Page Rank Tool
436,047,705 visitor(s) since 30th May, 2005.
All rights reserved. Site designed and maintained by DIVA ENTERPRISES PVT. LTD..
Note: Please use Internet Explorer (6.0 or above). Some functionalities may not work in other browsers.